1 |
Barrett-Connor, E., Ensrud, K. E., Harper, K., Mason, T. M., Sashegyi, A., Krueger, K. A., et al. (2003). Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes. Clinical Therapeutics, 25, 919-930.
DOI
ScienceOn
|
2 |
Colacurci, N., Manzella, D., Fornaro, F., Carbonella, M., & Paolisso, G. (2003). Endothelial function and menopause: Effects of raloxifene administration. The Journal of Clinical Endocrinology & Metabolism, 88, 2135-2140.
DOI
ScienceOn
|
3 |
Hernandez, E., Valera, R., Alonzo, E., Bajares-Lilue, M., Carlini, R., Capriles, F., et al. (2003). Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney International, 63, 2269-2274.
DOI
ScienceOn
|
4 |
Mosca, L., Grady, D., Barrett-Connor, E., Collins, P., Wenger, N., Abramson, B. L., et al. (2009). Effect of raloxifen on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke, 40, 147- 155.
DOI
ScienceOn
|
5 |
Vogelvang, T. E., Mijatovic, V., Kenemans, P., Teerlink, T., & van der Mooren, M. J. (2004). HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal women. Fertility and Sterility, 82, 1540-1549.
DOI
ScienceOn
|
6 |
Walsh, B. W., Kuller, L. H., Wild , R. A., Paul, S., Farmer, M., Lawrence, J. B., et al. (1998). Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. The Journal of the American Medical Association, 279, 1445-1451.
DOI
ScienceOn
|
7 |
Yildiz, M. F., Kumru, S., Godekmerdan, A., & Kutlu, S. (2005). Effects of raloxifene, hormone therapy, and soy isoflavone on serum highsensitive C-reactive protein in postmenopausal women. International Journal of Gynecology &Obstetrics, 90, 128-133.
DOI
ScienceOn
|
8 |
Zeng, S., Wu, Y., Zhang, Z., Yang, X., Hui, Y., Zhang, Y., et al. (2003). Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in postmenopausal women: A randomized clinical trial in Beijing. Chinese Medical Journal, 116, 1127-1133.
|
9 |
Simoncini, T., Genazzani, A. R., & Liao, J. K. (2002). Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation, 105, 1368-1373.
DOI
ScienceOn
|
10 |
Regitz-Zagrosek, V., Wintermantel, T. M., & Schubert, C. (2007). Estrogens and SERMs in coronary heart disease. Current Opinion in Pharmacology, 7, 130-139.
DOI
ScienceOn
|
11 |
Song, E. K., Yeom, J. H., Shin, H. T., Kim, S. H., Shin, W. G., & Oh, J. M. (2006). Effectiveness of raloxifene on bone mineral density and serum lipid levels in post-menopausal women with low BMD after discontinuation of hormone replacement therapy. Journal of Clinical Pharmacy and Therapeutics, 31, 421-427.
DOI
ScienceOn
|
12 |
Ministry of Health and Welfare and Korea Institute for Health and Social Affairs. (2005). The Third Korea National Health and Nutrition Examination Survey. Unpublished Report.
|
13 |
Nickelsen, T., Creatsas, G., Rechberger, T., Depypere, H., Erenus, M., Quail, D., et al. (2001). Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: Results from the Euralox 1 study. Climacteric, 4, 320-331.
DOI
|
14 |
Oh, E. K., Choi, H., Lee, C. M., Cho, Y. K., Kim, B. R., Ko, J. K., et al. (2006). A comparion of the effects of raloxifene and estrogen therapy on lipid profile and bone mineral density in postmenopausal women. Journal of Korean Postmenopause, 12, 19-27.
|
15 |
Reid, I. R., Eastell, R., Fogelman, I., Adachi, J. D., Rosen, A., Netelenbos, C., et al. (2004). A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Archives of Internal Medicine, 164, 871-879.
DOI
ScienceOn
|
16 |
Kung, A. W., Chao, H. T., Huang, K. E., Need, A. G., Taechakraichana, N., Loh, F. H., et al. (2003). Efficacy and safety of raloxifene 60 milligrams/ day in postmeno-pausal Asian women. The Journal of Clinical Endocrinology &Metabolism, 88, 3130-3136.
DOI
ScienceOn
|
17 |
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., et al. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. The British Medical Journal, 339, b2700.
DOI
|
18 |
Iwamoto, J., Sato, Y., Uzawa, M., Takeda, T., & Matsumoto, H. (2008). Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. Yonsei Medical Journal, 49, 119-128.
DOI
ScienceOn
|
19 |
Nanetti, L., Camilletti, A., Francucci, C. M., Vignini, A., Raffaelli, F., Mazzanti, L., et al. (2008). Role of raloxifene on platelet metabolism and plasma lipids. European Journal of Clinical Investigation, 38, 117-125.
DOI
ScienceOn
|
20 |
Hyung, H. K. & Kim, H. S. (2008). The effect of brisk walking exercise program on body composition, blood pressure, blood glucose and blood lipid for middle-aged women with obesity. Journal of Korean Biological Nursing Science, 10, 62-68.
과학기술학회마을
|
21 |
Anderson, G. L., Limacher, M., Assaf, A. R., Bassford, T., Beresford, S. A., Black, H., et al. (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. The Journal of the American Medical Association, 291, 1701-1712.
DOI
ScienceOn
|
22 |
Ettinger, B., Black, D. M., Mitkma, B. H., Knickerbocker, R. K., Nickelsen, T., Genant, H. K., et al. (1999). Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. The Journal of the American Medical Association, 282, 637-645.
DOI
ScienceOn
|
23 |
Grady, D., Herrington, D., Bittner, V., Blumenlhal, R., Davidson, M., Hlatky, M., et al. (2002). Cardiovascular disease outcomes during 6.8 years of hormones therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). The Journal of the American Medical Association, 288, 49-57.
DOI
ScienceOn
|
24 |
Griffiths, K. A., Sader, M. A., Skilton, M. R., Harmer, J. A., & Celermajer, D. S. (2003). Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease. Journal of the American College of Cardiology, 42, 698-704.
DOI
ScienceOn
|
25 |
Duvernoy, C. S., Kulkarni, P. M., Dowsett, S. A., & Keech, C. A. (2005). Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: Incidence, patient characteristics, and effect of raloxifene. Menopause, 12, 444-452.
DOI
ScienceOn
|
26 |
Engin-Ustun, Y., Ustun, Y., Meydanli, M. M., & Kafkasli, A. (2006). Effects of intranasal 17beta-estradiol and raloxifene on lipid profile and fibrinogen in hypercholesterolemic postmenopausal women: A randomized, placebo-controlled clinical trial. Gynecological Endocrinology, 22, 676-679.
DOI
ScienceOn
|
27 |
Collins, P., Mosca, L., Geiger, M. J., Grady, D., Kornitzer, M., Amewou- Atisso, M. G., et al. (2009). Effets of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for the Heart trial: Results of subgroup analyses by age and other factors. Circulation, 119, 922-930.
DOI
ScienceOn
|
28 |
Dias, A. R. Jr., Melo, R. N., Gebara, O. C., D'Amico, E. A., Nussbacher, A., Halbe, H. W., et al. (2005). Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women. Climacteric, 8, 63-70.
DOI
ScienceOn
|
29 |
Brussaard, H. E., Gevers, L. J., Frolich, M., Kluft, C., & Krans, H. M. (1997). Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia, 40, 843-849.
DOI
ScienceOn
|
30 |
Chu, S. H., Lee, M. K., Kowalski, J., Beck, J., & Schwertz, D. (2008). Effect of estrogen on ovariectomy-induced obesity in rats. Journal of Korean Biological Nursing Science, 10, 80-87.
과학기술학회마을
|